Borregaard (BRG) Pre-close call summary
Event summary combining transcript, slides, and related documents.
Pre-close call summary
16 Jun, 2026Executive summary
Outlook for 2026 reiterates expected sales volumes for BioSolutions and BioMaterials, with some product mix and pricing headwinds in the near term.
Geopolitical tensions, especially the Middle East conflict, are causing uncertainty, impacting demand and costs, but are seen as temporary with no structural demand change.
Cost inflation, particularly in energy and raw materials, is being addressed through targeted cost reduction measures and potential price adjustments.
Trading performance and revenue trends
BioSolutions full-year sales volume expected at 340,000 tons; Q2 volume around 90,000 tons, with a less favorable product mix than last year.
BioMaterials full-year sales volume guided at 155,000–160,000 tons, up from 146,000 tons in 2025; Q2 volume expected at 40,000–42,000 tons.
Fine Chemicals sales prices for bioethanol expected to remain stable; intermediates volume to increase versus 2025.
Profitability and margins
Average sales price for BioMaterials expected to be 3–4% lower in H1 2026 versus H2 2025, mainly due to product mix.
Net cost impact from raw materials, energy, and logistics estimated at NOK 40–60 million negative year-over-year for Q2, despite a 15% reduction in wood costs.
Energy costs are significantly higher, with Norwegian electricity prices up 75% and natural gas up over 90% year-over-year.
Latest events from Borregaard
- EBITDA fell 16% year-over-year as cost inflation and weaker BioSolutions weighed on results.BRG
Q1 202629 Apr 2026 - Specialisation, innovation, and sustainability drive growth and strong financial performance.BRG
Company presentation29 Apr 2026 - Specialisation, sustainability, and innovation drive growth and value in advanced biorefinery markets.BRG
Company presentation29 Apr 2026 - AGM approved a 12% dividend increase, board renewal, and strong financial and sustainability plans.BRG
AGM 202624 Apr 2026 - BioMaterials and BioSolutions volumes to grow in 2026, but pricing and cost risks persist.BRG
Pre-close call19 Mar 2026 - Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026 - Specialization, innovation, and sustainability drive robust growth and disciplined investment.BRG
CMD 202420 Jan 2026 - Q3 revenue and EBITDA rose on volume growth and expansion, but cost and market risks remain.BRG
Q3 202417 Jan 2026